Browse > Article

Relation between ERCC1 Expression in Sputum and Survival after Cisplatin-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer  

Yang, Sung Woo (Department of Internal Medicine, Kosin University, College of Medicine)
Choi, Pyoung Rak (Department of Internal Medicine, Kosin University, College of Medicine)
You, Hong Jun (Department of Internal Medicine, Kosin University, College of Medicine)
Kim, Jin Gu (Department of Internal Medicine, Kosin University, College of Medicine)
Oak, Chul Ho (Department of Internal Medicine, Kosin University, College of Medicine)
Jang, Tae Won (Department of Internal Medicine, Kosin University, College of Medicine)
Jung, Maan Hong (Department of Internal Medicine, Kosin University, College of Medicine)
Publication Information
Tuberculosis and Respiratory Diseases / v.60, no.2, 2006 , pp. 151-159 More about this Journal
Abstract
Background : Excision repair cross complementing gene 1 (ERCC1) not only has a protective role against carcinogens, but plays an important role in cisplatin-resistance via the repair of cisplatin-DNA adducts. This study investigated the association between the ERCC1 expression levels in sputum and survival after cisplatin-based chemotherapy in patients with inoperable non-small cell lung cancer (NSCLC). Methods : Using the sputum collected from 67 inoperable (stage IIIa-IV) NSCLC patients treated with either taxanes (33 cases) or gemcitabine (34 cases) plus cisplatin, the relative expression levels of ERCC1 and the expression of the tumor specific antigen, MAGE, were examined by the quantitative RT-PCR and RT-PCR, respectively. The response and survival were compared with the relative level of ERCC1 or MAGE expression and the treatment modality. Results : In the sputum, ERCC1 and MAGE was detected in 74.6% and 40.2% of patients, respectively. Using the median ERCC1 level, the patients were classified as having high or low ERCC1 expression. The median overall survival (MST) was significantly longer in patients with a high ERCC1 expression level than those with a low expression level (84 weeks vs. 44 weeks respectively, P=0.017). In the taxene-based treatment group, the MST was longer than the gemcitabine group (79 weeks vs. 47 weeks, respectively, P=0.03). The levels of ERCC1 were significantly higher in patients who were MAGE-positive (P=0.003). In the MAGE-negative patients, the MST was longer in the high ERCC1 group (103 weeks vs. 43 weeks, P=0.008), but not in the MAGE-positive patients (62 weeks vs. 44 weeks, P=0.348). Conclusion : ERCC1 expression in the sputum can be a prognostic factor for survival after chemotherapy in patients with inoperable NSCLC.
Keywords
ERCC1; MAGE; Non-small cell lung cancer; Sputum;
Citations & Related Records

Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Korea National Statistical Office. Death rate by the causes, 2004. http://www.kosis.nso.go.kr
2 Green MR. Targeting targeted therapy. N Engl J Med 2004;350:2191-3   DOI   ScienceOn
3 Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286-91
4 Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998;16:309-16   DOI
5 Arriagada R, Bergman B, Dunant A, le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60   DOI
6 Keller SM, Adak S, Wagner H, Herskovic A, Komaki R, Brooks BJ, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small-cell lung cancer. N Engl J Med 2000;343:1217-22   DOI   ScienceOn
7 Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8   DOI   ScienceOn
8 Rosell R, Felip E, Taron M, Majo J, Mendez P, Sanchez-Ronco M, et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 2004;10:4215s-9s   DOI
9 Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001;19:4298-304   DOI
10 van der Bruggen P, Traversari C, Chomez P, Lurquin C, de Plaen E, van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7   DOI
11 Carney DN. Lung cancer: time to move on from chemotherapy. N Engl J Med 2002;346:126-8   DOI   ScienceOn
12 de Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, de Smet C, et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 1994;40:360-9   DOI   ScienceOn
13 Butkiewicz D, Rusin M, Enewold L, Shields PG, Chorazy M, Harris CC. Genetic polymorphisms in DNA repair genes and risk of lung cancer. Carcinogenesis 2001;22:593-7   DOI   ScienceOn
14 Rosell R, Taron M, Ariza A, Barnadas A, Mate JL, Reguart N, et al. Molecular predictors of response to chemotherapy in lung cancer. Semin Oncol 2004;31 (Suppl 1):20-7
15 Fong KM, Sekido Y, Gazdar AF, Minna JD. Molecular biology of lung cancer: clinical implications. Thorax 2003;58:892-900   DOI   ScienceOn
16 Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non small-– cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39   DOI   ScienceOn
17 Spitz MR, Wu X, Wang Y, Wang LE, Shete S, Amos CI, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001;61:1354-7
18 Scientific Committee of Korean Academy of Tuberculosis and Respiratory Disease. The National Survey of Lung Cancer in Korea. Tuberc Respir Dis 1999;46:455-65   DOI
19 Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in nonsmall cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998;4:1087-100
20 Hande KR. Lung cancer: principles and practice. 2nd ed. Philadelphia: Lippincott Williams & Willkins; 2000. p. 270-83
21 Yook DS, Shin HS, Choi, P, Kim JH, Shin SH, Ok CH, et al. Expression of MAGE in the induced sputum of lung cancer patients. Tuberc Respir Dis 2002; 53:265-74   DOI
22 Cullinane C, Mazur SJ, Essigmann JM, Phillips DR, Bohr VA. Inhibition of RNA polymerase II transcription in human cell extracts by cisplatin DNA damage. Biochemistry 1999;38:6204-12
23 Dabholkar M, Vionnet J, Bostick-Brunton F, Yu JJ, Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994;94:703-8   DOI   ScienceOn
24 Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005;127:978-83   DOI   ScienceOn
25 Reed E. Platinum-DNA adducts, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998;24:331-44   DOI   ScienceOn
26 Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa nonsmall-cell lung cancer. J Clin Oncol 2002;20:247-53   DOI   ScienceOn
27 Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004;10:4939-43   DOI   ScienceOn
28 Bosken CH, Wei Q, Amos CI, Spitz MR. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 2002;94:1091-9   DOI
29 Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, et al. Association between polymorphism of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004;44:311-6   DOI   ScienceOn
30 Jheon S, Hyun DS, Lee SC, Yoon GS, Jeon CH, Park JW, et al. Lung cancer detection by a RT-nested PCR using MAGE AS 1: 6 common primers. Lung Cancer 2004;43:29-37   DOI   ScienceOn